Related Experiment Video
Updated: Mar 7, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Differential antiviral effects and immune responses in nasal and airway organoid during RSV infection: implications
Linmei Wang1, Lina Chen1, Lin Yang1
1Department of Pediatric Pulmonology, West China Second University Hospital, Sichuan University, Chengdu, China.
Insights
Respiratory syncytial virus (RSV) infection is severe in infants. Interferons (IFNs) reduce viral load and inflammation in pediatric airway organoids, with specific types showing differential efficacy by site.
Area of Science:
- * Virology and Immunology
- * Pediatric Respiratory Diseases
Background:
- * Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract infections in infants, leading to bronchiolitis and childhood asthma.
- * Infant RSV infections are significantly more severe than in adults, highlighting the need for effective treatments.
Purpose of the Study:
- * To investigate the efficacy of type I and type III interferons (IFNs) in pediatric nasal and airway epithelial organoids against RSV infection.
- * To compare the immune response in nasal versus airway epithelium and identify optimal interferon therapy strategies.
Main Methods:
- * Utilized pediatric nasal and airway epithelial organoids for RSV infection models.
- * Administered type I and type III IFNs to assess their impact on viral load and inflammatory mediators.
- * Employed transcriptome sequencing and multiplex cytokine profiling to analyze immune responses.
Main Results:
- * Both type I and type III IFNs significantly reduced RSV viral load and key inflammatory mediators (IL-6, CXCL8, IL-1α, TNF).
- * Nasal epithelium exhibited a more robust immune response compared to airway epithelium.
- * Interferon-lambda 1 (IFN-λ1) was most effective in suppressing nasal inflammation; Interferon-beta (IFN-β) did not worsen airway inflammation.
Conclusions:
- * Interferons show promise in reducing RSV-induced viral load and inflammation in pediatric airway models.
- * Findings suggest tailored IFN therapy, considering interferon type, delivery site, and dosage, is crucial for optimizing treatment.
- * Differential responses between nasal and airway epithelia provide insights for targeted therapeutic strategies.
Introduction:
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and young children, and it constitutes a significant risk factor for the development of bronchiolitis and subsequent childhood asthma. The severity of the disease is notably higher in infants compared to adults, underscoring the urgent need for effective therapeutic interventions.
Methods:
In our study, we utilized pediatric nasal and airway epithelial organoids to demonstrate that both type I and type III interferons (IFNs) markedly reduce viral load and downregulate key inflammatory mediators, including IL-6, CXCL8, IL-1α, and TNF, during RSV infection. Through transcriptome Sequencing and multiplex cytokine profiling of 46 immune mediators, we observed a more robust immune response in the nasal epithelium compared to the airway epithelium.
Results:
Notably, IFN-λ1 was most effective in suppressing inflammation in the nasal epithelium, whereas IFN-β did not exacerbate inflammatory responses in the airway epithelium.
Discussion:
These findings provide novel insights for optimizing clinical IFN therapy, particularly in terms of selecting the appropriate interferon type, delivery site, and dosing strategy.
